Log in or Sign up for Free to view tailored content for your specialty!
Infection News
Loop ileostomy may offer ‘viable surgical alternative’ for fulminant C. diff colitis
Since its introduction in 2011, adoption of diverting loop ileostomy for fulminant Clostridioides difficile colitis has more than doubled, and the procedure appeared to be a viable alternative to total colectomy, according to study findings published in JAMA Surgery.
Infants ‘naturally immunized’ against toxigenic C. difficile
Findings from a prospective cohort study of healthy infants suggest with toxigenic Clostridiodes difficile, or TCD, immune response against the toxins “natural immunization.
Log in or Sign up for Free to view tailored content for your specialty!
FDA accepts NDA for H. pylori therapy
RedHill Biopharma announced that the FDA has accepted a new drug application for its Helicobacter pylori infection therapy, Talicia.
HBV serostatus identification is critical before hemodialysis
A multistep process hemodialysis patients according to findings published in Infection Control Hospital Epidemiology.
Gastric cancer rates higher among patients treated for H. pylori
SAN DIEGO — Patients who receive antibiotic treatment for Helicobacter pylori infection experience gastric cancer at rates higher than the general population, and several risk factors can increase that risk even further, according to data presented at Digestive Disease Week.
MDROs jeopardize antibiotic prophylaxis for spontaneous bacterial peritonitis in patients with cirrhosis
Antibiotic prophylaxis of spontaneous bacterial peritonitis is less effective in cirrhotic patients with known multidrug-resistant organisms, according to a recent study.
Number of Crypto outbreaks increases 13% every year
The number of outbreaks caused by Cryptosporidium, or Crypto, increased approximately 13% each year between 2009 and 2017, researchers said.
Louisiana pharma partner agrees on model for novel HCV treatment plan
Louisiana Governor John Bel Edwards, Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics have agreed on a model to implement the health department’s innovative payment model for hepatitis C treatment, according to a press release.
Sovaldi with ribavirin safe, effective for children aged 3 years to 12 years
Treatment with Sovaldi and ribavirin was well-tolerated and highly effective in children aged 3 years to less than 12 years in pediatric patients with hepatitis C genotype 2 or genotype 3, according to a study published in Hepatology.
Chronic hepatitis B on the rise in Europe as acute cases decline
While most countries in the European Union and the European Economic Area have reported a decline in acute hepatitis B rates over the last decade, reports showed an increase in physicians discovering cases of chronic hepatitis B, according to data published by the European Center for Disease Prevention and Control.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read